



**SOLVE
ON.**

Data From Incyte's Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

October 13, 2023

WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 13, 2023-- Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company's clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) held October 13-15 in Phoenix.

"We look forward to sharing data from three oral presentations which add to our body of evidence on povorcitinib as a potential effective oral treatment option for patients living with hidradenitis suppurativa (HS)," said Kurt Brown, M.D., Global Program Head, Povorcitinib, and Associate Vice President, Drug Development, Inflammation & Autoimmunity, Incyte. "At Incyte, we are committed to relentlessly following the science to explore potential treatment options for immune-mediated dermatologic conditions such as HS, and are excited to share these data with the scientific community at this year's SHSA."

Key abstracts from Incyte-sponsored programs include:

Oral & Poster Presentations

Povorcitinib Impact on DLQI in Patients with Hidradenitis Suppurativa: Placebo-Controlled Phase 2 Study Results (Session: Clinical Research - Observational, Trials, and Treatment. Friday October 13, 4:00 p.m. – 4:10 p.m. ET)

HiSQoL Changes Among HiSCR Responders and Nonresponders in a Phase 2 Study of Povorcitinib (Session: Clinical Research - Observational, Trials, and Treatment. Friday October 13, 4:20 p.m. – 4:30 p.m. ET)

Baseline Patient Characteristics Associated with Achieving HiSCR with Povorcitinib: Phase 2 Secondary Analysis (Session: Clinical Research - Observational, Trials, and Treatment. Saturday October 14, 2:55 p.m. – 3:05 p.m. ET)

For full session details and data presentation listings, please see the SHSA 2023 (https://shsa.joynsymposium.com/conference_hall) online program.

About Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses that can lead to irreversible tissue destruction and scarring^{1,2}. Over-activity of the JAK/STAT signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS³. More than 150,000 patients in the U.S. are estimated to have moderate to severe HS⁴. Given the debilitating nature of condition, it can have a profoundly negative effect on patients' quality of life⁵.

About Povorcitinib (INCB54707)

Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for vitiligo, hidradenitis suppurativa (HS), prurigo nodularis, chronic spontaneous urticaria and asthma. Phase 3 studies in HS are also ongoing.

About Incyte Dermatology

Incyte's science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.

Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, hidradenitis suppurativa, lichen planus, lichen sclerosus and prurigo nodularis.

To learn more, visit the [Dermatology section](#) of [Incyte.com](https://www.incyte.com).

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](https://www.incyte.com) and follow [@Incyte](#).

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte's clinical development pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world, Incyte's dermatology program generally, and Incyte's goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA and other regulatory authorities; the efficacy or safety of Incyte's products; the acceptance of Incyte's products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte's reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2023. Incyte disclaims any intent or obligation to update these forward-looking statements.

¹ National Center for Advancing Translational Science Genetic and Rare Diseases Information Center. "Hidradenitis suppurativa." Available at: <https://rarediseases.info.nih.gov/diseases/6658/hidradenitis-suppurativa>

² Kirby J, et al. Efficacy and Safety of the Janus Kinase 1 Inhibitor Povorcitinib (INCB054707) in Patients with Hidradenitis Suppurativa: Results from a Randomized, Placebo-Controlled, Phase 2 Dose-Ranging Study. Presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress, September 7-10, 2022.

³ Solimani, F., Meier, K., & Ghoreschi, K. (2019). Emerging topical and systemic JAK inhibitors in dermatology. *Frontiers in immunology*, 10, 2847.

⁴ McMillan, K. Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States. *Am J Epidemiol*. 2014 Jun 15;179(12):1477-83. doi: 10.1093/aje/kwu078. Epub 2014 May 8.

⁵ Sabat, R., Jemec, G. B., Matusiak, Ł., Kimball, A. B., Prens, E., & Wolk, K. (2020). Hidradenitis suppurativa. *Nature reviews Disease primers*, 6(1), 18.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231013811765/en/): <https://www.businesswire.com/news/home/20231013811765/en/>

Media

media@incyte.com

Investors

ir@incyte.com

Source: Incyte